Considering exon 17 was the major mutant site in AML as reported before [15, 16], we further divided 41 patients, available for analysis of KIT mutation site, into two groups: patients with exon 17 (n = 25) and others (n = 16) and made comparison between the subgroups (Table 2). Here, KIT is linked to acute myeloid leukemia.